Velaglucerase beta not checked

CANbridge Life Sciences Ltd.

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
1 active
1 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks with two weeks of follow-up through Week 39 (9 months).”In the company’s words, NCT07847411 on ClinicalTrials.gov
Tested for
Gaucher Disease, Gaucher Disease Type 1, Gaucher Disease Type 3
Main trialPhase 3
“This is a Phase 3, multicenter, open-label, single-arm study to evaluate the safety, efficacy, PK, PD, and immunogenicity of velaglucerase beta in untreated children with GD1 or GD3 for 39 weeks.”In the company’s words, NCT07847411 on ClinicalTrials.gov

Other drugs for Gaucher Disease

All 7 drugs for Gaucher Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 25 Feb 2028 Study of Velaglucerase Beta ERT in Children With Gaucher Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Velaglucerase beta

Following is part of Solo: you see every change to Velaglucerase beta the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in